Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2015', provides an overview of the Prader-Willi Syndrome (PWS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Prader-Willi Syndrome (PWS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Prader-Willi Syndrome (PWS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Prader-Willi Syndrome (PWS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Prader-Willi Syndrome (PWS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Prader-Willi Syndrome (PWS) Overview 7
Therapeutics Development 8
Pipeline Products for Prader-Willi Syndrome (PWS) - Overview 8
Pipeline Products for Prader-Willi Syndrome (PWS) - Comparative Analysis 9
Prader-Willi Syndrome (PWS) - Therapeutics under Development by Companies 10
Prader-Willi Syndrome (PWS) - Therapeutics under Investigation by Universities/Institutes 11
Prader-Willi Syndrome (PWS) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Prader-Willi Syndrome (PWS) - Products under Development by Companies 16
Prader-Willi Syndrome (PWS) - Products under Investigation by Universities/Institutes 17
Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development 18
Alize Pharma SAS 18
Chong Kun Dang Pharmaceutical Corp. 19
Essentialis, Inc. 20
Ferring International Center S.A. 21
LG Life Sciences, Ltd. 22
P2D Bioscience 23
Rhythm Pharmaceuticals 24
Prader-Willi Syndrome (PWS) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AZP-531 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
beloranib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
betahistine hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
carbetocin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
diazoxide choline CR - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
K-671 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
OV-401 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
setmelanotide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Antagonize Ghrelin Receptor for Prader-Willi Syndrome - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
somatropin (recombinant) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Prader-Willi Syndrome (PWS) - Recent Pipeline Updates 49
Prader-Willi Syndrome (PWS) - Dormant Projects 56
Prader-Willi Syndrome (PWS) - Product Development Milestones 57
Featured News & Press Releases 57
Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies 57
May 28, 2015: Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome 58
May 08, 2015: Zafgen Presents Positive Safety And Efficacy Data From Phase 2 Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015 59
Mar 26, 2015: Essentialis Presents Results From the First Phase of Clinical Study PC025 Evaluating DCCR in the Treatment of Prader-Willi Syndrome at ACMG Annual Clinical Genetic Meeting 60
Mar 02, 2015: Alize Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome 61
Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research 62
Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome 62
Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome 63
Jul 10, 2014: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome 64
Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2015 8
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Comparative Analysis by Unknown Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Prader-Willi Syndrome (PWS) - Pipeline by Alize Pharma SAS, H2 2015 18
Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 19
Prader-Willi Syndrome (PWS) - Pipeline by Essentialis, Inc., H2 2015 20
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center S.A., H2 2015 21
Prader-Willi Syndrome (PWS) - Pipeline by LG Life Sciences, Ltd., H2 2015 22
Prader-Willi Syndrome (PWS) - Pipeline by P2D Bioscience, H2 2015 23
Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals, H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Stage and Target, H2 2015 27
Number of Products by Stage and Mechanism of Action, H2 2015 29
Number of Products by Stage and Route of Administration, H2 2015 31
Number of Products by Stage and Molecule Type, H2 2015 33
Prader-Willi Syndrome (PWS) Therapeutics - Recent Pipeline Updates, H2 2015 49
Prader-Willi Syndrome (PWS) - Dormant Projects, H2 2015 56